One of the most common concerns raised by cluster headache patients starting the Vitamin D3 Anti-Inflammatory Regimen is whether 10,000 IU per day is safe for long-term use. A 2025 retrospective study on high-dose vitamin D3 in psoriasis patients provides some of the most directly relevant safety data we have seen to date, and the findings are genuinely reassuring.
Study Overview
This retrospective analysis, led by Mahtani and colleagues, evaluated 95 adults with chronic psoriasis who were treated for up to twelve months using individualised daily doses of vitamin D3 ranging from 30,000 to 60,000 IU per day. All participants discontinued immunosuppressants, corticosteroids, biologics and phototherapy during the study period, allowing for an isolated assessment of vitamin D3's effects.
At baseline, 65 percent of patients were vitamin D deficient, with serum 25(OH)D levels below 30 ng/mL. Nearly 40 percent had levels under 20 ng/mL, representing severe deficiency.
Dosing was stratified by body weight: 30,000 IU per day for individuals between 60 and 75 kg and 40,000 IU per day for those above 75 kg. Patients with 25(OH)D below 20 ng/mL received a loading dose of 600,000 IU over ten days before transitioning to daily dosing. Those with levels between 20 and 29 ng/mL received a 300,000 IU load across five days. Critically, doses were adjusted according to parathyroid hormone (PTH) suppression and ionised calcium values rather than 25(OH)D levels alone, reflecting the Coimbra protocol's approach to vitamin D resistance in autoimmune conditions.
Clinical Findings
After twelve months, mean PASI scores (Psoriasis Area and Severity Index) improved from 17.83 to 6.52. Seventy-seven percent of participants achieved at least a 50 percent reduction in disease severity and over 50 percent surpassed a 75 percent improvement. Serum 25(OH)D concentrations rose above 100 ng/mL across the cohort while PTH levels fell from a mean of 52.5 pg/mL to 32.5 pg/mL.
Ionised calcium remained within normal limits throughout the study. No cases of hypercalcemia, renal dysfunction or vitamin D toxicity were observed, even in patients receiving up to 60,000 IU per day for several months. When therapy is guided by calcium and PTH monitoring, vitamin D3 can be administered safely at doses well above conventional guidelines.
Why This Matters to Cluster Headache Patients
For cluster headache patients using or exploring the Vitamin D3 Anti-Inflammatory Regimen, this study is particularly relevant. The loading protocol used in Mahtani's cohort, 600,000 IU over ten days for patients below 20 ng/mL, is nearly identical to the 600,000 IU loading schedule used in the CH protocol for episodic cluster headache.
The maintenance doses in the psoriasis cohort were significantly higher than those used in CH. Mahtani's patients required 25,000 to 45,000 IU per day on average, with some patients maintained at 50,000 IU per day for several months before tapering. By comparison, the standard CH regimen typically prescribes 10,000 IU per day. Doses often perceived as high in the CH community are, in this context, modest.
Reassessing What "High Dose" Really Means
Many cluster headache patients are initially anxious about 10,000 IU per day, fearing it exceeds safe limits. The Mahtani data make clear that this amount sits at the lower end of an established therapeutic range for chronic inflammatory conditions. Doses four to five times higher have been administered safely under appropriate laboratory oversight.
For patients with refractory cluster headache who may need to escalate beyond 10,000 IU per day to achieve PTH suppression and sustained remission, this study provides strong independent clinical evidence that such dosing can be physiologically tolerated long term.
Conclusion
Mahtani's 2025 study adds meaningfully to the growing body of evidence supporting high-dose vitamin D3 as both effective and safe when guided by individual responsiveness rather than arbitrary limits. For cluster headache patients following the Vitamin D3 Anti-Inflammatory Regimen, it offers a concrete layer of reassurance. The loading and maintenance strategies used in psoriasis closely mirror those used for CH, but at generally lower doses.
Rather than viewing 10,000 IU per day as excessive, patients can take confidence that this amount is well within a physiologically validated range, and that even higher titrations, when needed for complete CH remission, are safe under medical supervision with appropriate lab monitoring.
Citation: Mahtani R., Singh S., Nair P. M., Singh S. P., Goyal M. (2025). Prolonged high dose daily oral vitamin D3 in the management of psoriasis: A retrospective chart analysis. IP Indian Journal of Clinical and Experimental Dermatology, 11(3), 288-296. https://doi.org/10.18231/j.ijced.89447.1758864688
Leave a Comment